First Amendment Suit: FDA Draws The Line At Amarin's Heart Disease Claim

Trying to forestall preliminary injunction, FDA's Woodcock doesn't object to Amarin's reprint distribution, but says firm needs strong incentive to complete its cardiovascular outcomes study.